Drug intelligence / Profile preview

AXT-1004

Development stage: Preclinical
Lead developer: Axter Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

AXT-1004 is a preclinical-stage small molecule inhibitor developed by Axter Therapeutics. It is designed to target Pan-MLL (Mixed Lineage Leukemia) proteins, which are frequently involved in chromosomal translocations that drive aggressive forms of leukemia and certain solid tumors. By inhibiting the MLL complex, AXT-1004 aims to disrupt the epigenetic dysregulation that promotes oncogenic gene expression. The drug is currently being investigated for the treatment of hematologic malignancies and various solid tumors.

Targets

Histone-lysine N-methyltransferase 2 family (Mixed lineage leukemia protein family)

Beyond the preview

Go deeper on AXT-1004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AXT-1004.

Explore the full profile